Unvaccinated Americans are snubbing the Johnson & Johnson vaccine
Unvaccinated Americans are not keen on receiving the Johnson & Johnson COVID-19 shot, even after a temporary pause on its use was lifted last week, a Washington Post/ABC News poll found.
Only 22 percent of people in the demographic are willing to get the vaccine, which has been linked to very rare but serious cases of blood clots.
While that number can likely be partially chalked up to folks who are not willing to get vaccinated at all, a significantly higher number of unvaccinated Americans consider the Pfizer-BioNTech and Moderna vaccines to be safe.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The good news for the United States is that the country has more than enough supply of the other two approved vaccines for everyone who wants to be vaccinated. Still, the hesitancy surrounding the Johnson & Johnson vaccine could have ramifications — it's easier to store than its fellow vaccines, so it could come in handy for hard-to-reach populations, the Post notes, and it only requires a single-shot, which could help buck the trend of some people not going to get their second Pfizer or Moderna dose.
Those attributes also mean Johnson & Johnson is theoretically a crucial weapon in vaccinating much of the world, so it's worth keeping an eye on whether that hesitancy extends beyond the U.S.
The Washington Post/ABC News poll was conducted among 1,007 adults in the U.S. between April 18-21. The margin of error is 3.5 percentage points. Read more at The Washington Post.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
US bans final type of asbestos
Speed Read Exposure to asbestos causes about 40,000 deaths in the U.S. each year
By Peter Weber, The Week US Published
-
Seattle Children's Hospital sues Texas over 'sham' demand for transgender medical records
Speed Read Texas Attorney General Ken Paxton subpoenaed records of any Texan who received gender-affirming care at the Washington hospital
By Peter Weber, The Week US Published
-
Afghanistan has a growing female suicide problem
Speed Read The Taliban has steadily whittled away women's and girls' rights in Afghanistan over the past 2 years, prompting a surge in depression and suicide
By Peter Weber, The Week US Published
-
US life expectancy rose in 2022 but not to pre-pandemic levels
Speed Read Life expectancy is slowly crawling back up
By Devika Rao, The Week US Published
-
Vallance diaries: Boris Johnson 'bamboozled' by Covid science
Speed Read Then PM struggled to get his head around key terms and stats, chief scientific advisor claims
By The Week UK Published
-
An increasing number of dog owners are 'vaccine hesitant' about rabies
Speed Read A new survey points to canine vaccine hesitancy
By Devika Rao, The Week US Published
-
Anger may be a powerful motivator for tough goals, new study suggests
Speed Read Keeping your cool might actually be less efficient than letting your anger drive you
By Theara Coleman, The Week US Published
-
A tropical skin disease is making the rounds in the US
Speed Read Leishmaniasis is endemic to the country and can cause ulcers and disfiguration
By Devika Rao, The Week US Published